The headline reads as positive (64% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › CDNA
Caredx, Inc. (CDNA) stock analysis
BUY 54% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Caredx, Inc. (CDNA) BUY with 54% confidence at a price of $71.52. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$71.52
Technical picture
The 14-day RSI is 69, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.3x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $21.49 and the swing low is $15.56; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The company reports a profit margin of 24.2% and revenue growth of +52.2%.
In its latest quarter it earned $0.37 per share, which beat the $0.23 analysts expected, with revenue +52.2% year over year.
Wall Street's average rating is 1.6 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $65.33.
Trade plan from the model
The model's long / bullish plan uses an entry near $71.52, a target of $88.37 (+23.6%) and a stop-loss at $63.17 (-11.7%).
That is a reward-to-risk ratio of about 2.0 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$71.52
Target$88.37
Stop-loss$63.17
Reassess byNov 19, 2026
Research notes
CareDx’s bull case is accelerating transplant-testing demand: Q3 revenue rose 39% year over year to $139 million, testing volume increased 51%, adjusted EBITDA doubled to $30 million, and management raised FY2026 guidance to $520–530 million of revenue. The bear case centers on valuation after a roughly 394% 12-month rally, plus dependence on reimbursement decisions, potential payment bundling or test-frequency limits, and execution risks from acquisitions and integration. The major recent catalyst was the October 29 earnings report, which beat expectations and highlighted stronger profitability, while new AlloSure Kidney data linked elevated test results to materially higher graft-loss risk and reinforced the clinical-adoption story.
The model's one-paragraph read
Leans BUY — composite score +0.54 (BUY). Technicals: RSI 69.26, MACD bullish, price above SMA50. Fundamentals: margin 24.2%, revenue growth 52.2%. Financial results: YoY revenue +52.2%, last EPS surprise +60.9%. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bearish order block. FinGPT news read: positive. Internet research: CareDx’s bull case is accelerating transplant-testing demand: Q3 revenue rose 39% year over year to $139 million, testing volume increased 51%, adjusted EBITDA doubled to $30 million, and management raised FY2026 guidance to $520–530 million of revenue. The bear case centers on valuation after a roughly 394% 12-month rally, plus dependence on reimbursement decisions, potential payment bundling or test-frequency limits, and execution risks from acquisitions and integration. The major recent catalyst was the October 29 earnings report, which beat expectations and highlighted stronger profitability, while new AlloSure Kidney data linked elevated test results to materially higher graft-loss risk and reinforced the clinical-adoption story. Suggested levels: entry $71.52, target $88.37, stop-loss $63.17, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for CDNA
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 54% | $71.52 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on CDNA
Oct 29, 2026 · CareDx Raises Guidance For A Third Straight Quarter As Transplant Volume Accelerates, But One-Time Items And A Softer Implied Q4 Temper The Beat
- Oct 29, 2026: CareDx Raises Guidance For A Third Straight Quarter As Transplant Volume Accelerates, But One-Time Items And A Softer Implied Q4 Temper The Beat (Earnings Whispers)
- Oct 29, 2026: CareDx: Q3 Earnings Snapshot (Associated Press)
- Oct 29, 2026: CareDx Announces Third Quarter 2026 Financial Results (Business Wire)
Frequently asked questions
Is CDNA a buy right now?
As of Oct 29, 2026, our automated model rates Caredx, Inc. (CDNA) BUY with 54% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for CDNA?
The model's most recent plan targets $88.37 with a stop-loss at $63.17, from an entry near $71.52.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.